Wright State University

CORE Scholar
Browse all Theses and Dissertations

Theses and Dissertations

2017

Usage of Extracellular Microvesicles as Novel and Promising
Therapeutic Tool in Wound Healing
Sami Gamaleddin F. Alsabri
Wright State University

Follow this and additional works at: https://corescholar.libraries.wright.edu/etd_all
Part of the Pharmacology, Toxicology and Environmental Health Commons

Repository Citation
Alsabri, Sami Gamaleddin F., "Usage of Extracellular Microvesicles as Novel and Promising Therapeutic
Tool in Wound Healing" (2017). Browse all Theses and Dissertations. 1861.
https://corescholar.libraries.wright.edu/etd_all/1861

This Thesis is brought to you for free and open access by the Theses and Dissertations at CORE Scholar. It has
been accepted for inclusion in Browse all Theses and Dissertations by an authorized administrator of CORE
Scholar. For more information, please contact library-corescholar@wright.edu.

USAGE OF EXTRACELLULAR MICROVESICLES AS A NOVEL
AND PROMISING THERAPEUTIC TOOL IN WOUND HEALING
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science

By

SAMI GAMMALEDDIN F ALSABRI

BSc. Pharm, University of Tripoli, Libya, 2009

2017

Wright State University

WRIGHT STATE UNIVERSITY
GRADUATE SCHOOL

July 15, 2017

I HEREBY RECOMMEND THAT THESIS PREPARED UNDER MY SUPERVISION
BY Sami Gammaleddin F Alsabri ENTITLED Usage of Extracellular Microvesicles

as a Novel and Promising Therapeutic Tool in Wound Healing. BE ACCEPTED
IN PARTIAL FULLFILMENT OF THE REQUIREMENTS FOR THE DEGREE OF
Master of Science.
____________________________
Richard Simman,
M.D., FACS., FACCWS
Thesis Advisor
____________________________
Debra A. Mayes, Ph.D.
Thesis Co-Advisor
___________________________
Jeffrey Bryant Travers, M.D.,
Ph.D., Professor and Chair,
Department of Pharmacology and
Toxicology

Thesis Committee
_________________________
Richard Simman. M.D., FACS., FACCWS
_________________________
Debra A. Mayes, Ph.D.
_________________________
Ulas Sunar, Ph.D.
_________________________
Terry Oroszi, Ed.D.
_________________________
Robert E.W. Fyffe, Ph.D.
Vice President for Research and
Dean of the Graduate School.

ii

Abstract
Alsabri, Sami Gammaleddin F. M.S. Department of Pharmacology and Toxicology,
Wright State University, 2017. Usage of Extracellular Microvesicles as Novel and
Promising Therapeutic Tool in Wound Healing.
Introduction Extracellular Microvesicles (EMVs) can carry genetic messages and
biologically active proteins throughout tissues and the body. Because of their transport
capabilities, EMVs play an important role both diseased and healthy conditions. For
example, EMVs play an important regenerative role in many damaged tissues. In the
current studies, we examine the role of EMVs in epithelial wound healing. The potential
use of EMVs as drug delivery vehicles has gained considerable scientific interest because
they can be delivered in circulation, can be targeted to specific areas/cells, and can pass
natural barriers. In the current work, we investigate the potential of EMVs or EMVs loaded
with growth factors as a tool to enhance cell migration in order to accelerate epithelial
wound healing.
Material and Methods Spontaneously immortalized skin keratinocyte and macrophage
cells were stressed for 48 h by serum free media to enhance the release of the EMVs from
keratinocytes (KMVs) and macrophages (MMV). The EMVs from both cell lines were
isolated and collected using a centrifugation process. Specifically, the collected serum free
media were centrifuged at 4 °C (500 × g for 10 minutes followed by 2,000 × g for 20
minute). The supernatant was then centrifuged at 24,000 × g for 2 hours to isolate EMVs.
EMVs were “loaded” with growth factors by incubating them for 1.5 h at room temperature
iii

with PDGF, TGF-β, VEGF, and FGF (25ng/ml per each). These “loaded” EMVs were then
ultra-centrifuged at 176,000 x g for 3 h to re-pellet the loaded microveiscles derived from
keratinocytes KMVs (LKMVs) or macrophages MMVs (LMMVs).
In order to evaluate the role of microvesicles on cutaneous wound healing, we chose
the in vitro wound scratch assay to evaluate the cell migration rate and the wound healing
percent after adding of KMVs, LKMVs, MMVs, and LMMVs separately to Epidermal
keratinocytes culture. Epidermal keratinocytes were plated into 6 well plates, and wound
scratch was made using 10 µl pipette tip. The model was visualized by 10 x magnification
power of EVOS XL Core Cell Imaging System and analyzed using Mat lab software to
measure wound area.
MTT assay was used to evaluate the proliferative effect of KMVs, LKMVs, MMVs,
and LMMVs on Epidermal keratinocytes. The loading was confirmed by using BioPlex
Pro cytokine assays.
Results after 72 h, the wound area in the EMVs (KMVs & MMVs) and LEMVs (LKMVs
& LMMVs) treated groups showed a significant decrease in wound area and a remarkable
ability to repair the wound area as compared with the control group (P < 0.0001). The
percent of wound healing was almost three times more in KMVs and MMVs treated groups
(57.85 % ±3.13, 69.84 % ± 4.87, respectively), and four times in LKMVs and LMMVs
treated groups (80.10% ±3.50, 90.87% ±2.00, respectively) when compared to the control
groups (21.74 % ± 2.389) (P < 0.0001). Furthermore, the migration rate in the presence of
KMVs and MMVs (0.008810 ± 0. 0006856, 0.01085 ±0.0007964 mm2/h, respectively)
iv

and LKMVs and LMMVs (0.01470 ± 0.0009428, 0.01767 ±0.001163 mm2/h,
respectively) were enhanced when compared to the control group (0. 003820 ± 0. 0003760
mm2/h).
Conclusion EMVs and Loaded EMVs have a potential regenerative effect in wound
healing, which promotes and enhances cell migration and proliferation, resulting in
accelerated wound closure. Based on these finding, we suggest that EMVs are a novel and
promising therapeutic tool for epithelial wound healing.
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Introduction
Skin is the largest organ in the body. It works as a protective layer against toxins
and microorganisms, and provides chemical protection against invasion by toxins and
microorganisms. Skin also plays an important role in thermoregulation and prevention of
dehydration. (Choi, Uyama, Lee, & Sung, 2015)

Wounds
A wound can be defined as a breakdown in the protective function of the skin.
Wounds can also be defined as disruption in the epithelial lining of the skin or mucosa due
to either physical or thermal injury (Dhivya, Padma, & Santhini, 2015). Generally, wounds
are classified as acute or chronic. Clinically, acute wounds are defined as wounds with high
tendency to heal in a short period of time (< 3 months), while chronic wounds have little
or no tendency to healing (≥ 3 moths).

Chronic wounds
Chronic wounds have increased in prevalence over the last few decades. Chronic
wounds affect 1-2 % of the population in the United States, which results in an increase in
the health care burden. These injuries cost the US health care system around 50 billion
dollars yearly, with an average cost of $3.349 to 9.358 per wound. Furthermore, current
treatments for chronic wounds do not guarantee wound closure, and recurrence is common.
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Therefore, the development of effective chronic wound treatments is an important issue
that could increase the effectiveness of health care resources worldwide (Gainza et al.,
2015). Scientists have not only focused on developing new modalities of treatment, but
also improving the efficacy of existing treatments. Here we focus upon the use of growth
factors (GFs) for wound healing (Gainza et al., 2015).

Wound healing
Epithelial wound healing occurs in stages. Understanding the stages of wound healing
at the molecular level is essential to developing treatment. This may helps in not only reduce
morbidity and mortality related to abnormal or prolonged wound healing but also in finding
and introducing new approaches and therapeutics tools. Cutaneous wound healing is a

multistep and highly sophisticated systematic process. It includes many cell types, soluble
mediators, and extracellular matrices (Robson et al., 2001) a long with a highly dynamic
coordination between complex cascades of cellular events. These events begin when
wounding occurs in a process meant to restore and/or replace the damaged and/or missing
tissues (Rieger et al., 2014). Furthermore, wound healing is characterized by a series of
overlapping time dependent phases. These include the hemostatic phase (time of injury up
to several hours after injury), inflammatory phase (1 to 3 days), proliferative phase (4 to
21 days), and remodeling phase (21 days up to 18 months) (Landén et al., 2016). Disruption
in any of these phases results in healing impairment and the potential for chronic wounds
(Landén et al., 2016, Shi et al., 2013). Unfortunately, current therapeutic tools for chronic
wounds still do not achieve the complete healing, and do not prevent wound recurrence.
Thus, the development of a novel, effective treatment is needed. (Dhivya et al., 2015;
Rosique, Rosique, & Farina Junior, 2015).
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Growth factors in wound healing
The wound healing process is affected by growth factors. Therefore, growth factors
have been extensively studied over the past decades. Growth factors contribute and regulate
the cell migration and proliferation in order to accomplish healing as a response to tissue injury
(Molloy, Wang, & Murrell, 2003; Rosique et al., 2015). Several growth factors have been
proven to have a role in inflammation (explained below) where they have been shown to
improve wound healing (Efron and Moldawer 2004). Furthermore, down regulation of growth
factor proteins has been reported in chronic wounds and has been hypothesized to be one
possible cause of wound chronicity (Barrientos et al., 2008).

Platelet derived growth factor (PDGF)
PDGF is produced by secreted by platelets, macrophages, vascular endothelium,
fibroblasts, and keratinocytes. PDGF induces cell proliferation, angiogenesis and
chemotaxis. In fact, PDGF has a significant role in each phase of healing process (Efron
and Moldawer 2004).
During the inflammatory phase, PDGF serves as a strong stimulant for mitogenicity
and chemotaxis of neutrophils, macrophages, fibroblasts, and smooth muscle cell
migration to the wound site (Barrientos et al., 2008). PDGF also enhances the release of
several growth factors. For example, TGF-β can be produced by macrophages as a result
of direct induction of PDGF. Later, TGF-β along with PDGF enhance macrophage
mediated tissue cleanup, and formation of granulation tissue in the proliferation phase.
Regarding to angiogenesis, in vitro PDGF, synergistically with hypoxia, shows
ability to induce formation of new blood vessels by enhancing of VEGF expression, and it
is particularly essential in in blood vessel maturation (Hu & Huang, 2015). In vitro PDGF
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has been shown to induce reepithelialization through upregulation of IGF-1 and
thrombospondin-1 synthesis, which increase keratinocyte motility, delays proteolytic
degradation, and indorses a proliferative response in keratinocytes in the wound healing
(Barrientos et al., 2008). Similarly, PDGF can increase fibroblast proliferation and regulate
collagen production, which are required during the proliferative phase of wound healing
(Hu & Huang, 2015).
In the remolding phase, PDGF can increase the degradation of collagen by
regulating matrix metalloproteinases (Jinnin et al., 2004). In all stages of wound healing,
PDGF plays a vital role by stimulating the release of the pro-healing cytokines at site of
injury.

Transforming growth factor beta (TGF-β)
TGF-β is a family of pluripotent cytokines. TGF-β has three isoforms: TGF-β 1, 2,
and 3 with a dominant role of TGF-β 1 in cutaneous wound healing. It can be released by
keratinocytes, platelets, monocytes, macrophages, and fibroblasts (Rolfe et al., 2007 and
Barrientos et al., 2008)
In homeostasis normal conditions, TGF-β has been found to regulate the
keratinocyte cell cycle and inhibit proliferation. Therefore, TGF-β plays a role in
maintaining skin homeostasis. TGF-β is a crucial key factor in the wound healing process
(Siegel & Massagué 2003, Ramirez et al., 2014). It plays a significant regulatory role at all
the tissue regeneration stages, including, the inflammation, re-epithelialization,
angiogenesis, and granulation tissue formation (Efron and Moldawer 2004, Guasch et al.,
2007, Barrientos et al., 2008).
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In wounds, TGF-β has been found to have pleiotropic effects, and regulates the
functions of keratinocytes, fibroblasts, endothelial cells, monocytes, and other cell types
that are required in the regenerative process (Ramirez et al., 2014).
In nonhealing wounds, booth in vitro and in vivo data show that TGF-β can suppress
the growth and maintenance of epidermal homeostasis (Guasch et al., 2007). Multiple
studies have also demonstrated that TGF-β expression is suppressed in the epidermis of
chronic wounds (Ramirez et al., 2014). Several mouse models have shown that exogenous
application of TGF-β enhanced wound healing by activating TGF-β signaling (Barrientos
et al., 2008). Clinically, in chronic ulcers, suppression of TGF-β signaling may contribute
to the loss of tissue homeostasis because of the hyperproliferation and the inability of
keratinocytes to migrate, epithelialize, and close the wound.
During the inflammatory stage, TGF-β plays a pro-inflammatory role as a
chemotactic agent for monocytes infiltration to the wound site. It can also differentiate
macrophages that clean up the wound site, and play an anti-inflammatory role. During the
proliferative stage. In proliferative stage, TGF-β is involved in angiogenesis and initiates
granulation tissue formation. This occurs by up-regulating the expression of fibronectin,
collagen types I and III, vascular endothelial growth factor (VEGF), and protease inhibitors.
TGF-β also down regulates MMP expression, which further promotes the accumulation of
collagen fibers (Barrientos et al., 2008). Furthermore, TGF-β induces the wound
contraction by inducing smooth muscle alpha actin expression in fibroblasts and myofibroblast differentiation (Van De Water et al., 2007).
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Vascular endothelial growth factor (VEGF)
VEGF, also called vascular permeability factor, is a homodimeric glycoprotein, and
one of the most important vascular regulators of vasculogenesis and angiogenesis during
the injury healing process (Hoeben et al., 2004). VEGF is secreted from platelets,
keratinocytes, macrophages, neutrophils, endothelial cells, smooth muscle cells, and
fibroblasts (Barrientos et al., 2008). VEGF is involved in wound repair by triggering
angiogenesis, chemotaxis, and inducing vascular permeability (Bao et al., 2009) during the
during the wound healing process (Cooper et al., 1999).
VEGF has distinctive effects on many components of the wound healing cascade,
comprising angiogenesis, epithelialization, and collagen deposition (Tomic-Canic et al.,
2007). Since angiogenesis has a vital role in the wound reconstructing process, VEGF
(alone or in combination therapy) may be utilized in the future for patients with non-healing
chronic wounds. According to in vitro studies, VEGF initiates the early events in
angiogenesis, chiefly migration and proliferation of endothelial cell (Lamalice et al., 2007).

Fibroblast Growth Factor (FGF)
Since its discovery as a family of growth factors, FGFs are known to play a role in
a variety of biological processes including differentiation, migration, proliferation,
angiogenesis, and wound healing (Nakamichi et al., 2016). FGFs are released from many
cells including macrophages, mast cells, keratinocytes, fibroblasts, smooth muscle cells in
the wound environment. During the inflammatory stage, FGF has a role in recruiting
several inflammatory cells, such as neutrophils and monocytes to the wound site. In
addition, FGF induces the expression of several chemokines, and encourages mitogenesis
of endothelial cells (Nakamichi et al., 2016). As a growth factor, FGF plays a critical role
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in re-epithelialization, formation of granulation tissue and tissue remodeling. Several in
vitro studies have revealed that FGF controls extracellular matrix deposition, enhances
both keratinocyte migration and proliferation augments fibroblast migration, activates the
release of collagenase, and additionally improves endothelial cell growth and migration.
(Teven et al., 2014). In vivo studies, FGF administration can improve healing in diabetic,
ischemic, and bacterial contaminated wounds. In clinical trials, FGF administration has
proven to be efficacious for earlier wound closure in pressure ulcers, burns, chronic dermal
ulcers, and operative wounds (Barrientos et al., 2008).

Extracellular microvesicles (EMVs)
EMVs are lipid membrane-bound vesicles, which are shed by almost all cell types
into the extracellular environment. The release of EMVs is one of the ways cells
communicate in both healthy and pathological conditions (Camussi et al., 2010). These
EMVs can deliver many bioactive molecules such as cytokines and growth factors (Fais et
al., 2016). Likewise, they can deliver a biological message to recipient cells in normal
physiological and diseased conditions (Fais et al., 2016, Waldenström et al., 2012).
Moreover, EMVs have been found to have a regenerative effect in several tissues from
several origins. Recently, phase IV double-blinded clinical trial conducted by Simman et
al. showed that there is a correlation between EMVs and the rate of wound healing
(Simman et al., 2016). The decline of growth factors in chronic wounds, the need for a
more effective treatment for wounds, and the evidence for the potential role of EMVs in
tissue repair, have prompted us to investigate, the potential effect of growth factors loaded
EMVs may have to enhance and accelerate wound healing.
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EVs as drug delivery systems
Today, EMVs are extensity under scientific investigation as a potential drug
delivery system because of their capabilities to cross the biological barriers and targeting
specific cells. Furthermore, loading of the therapeutic agents into EMVs increased the
circulation time, preserve the therapeutic activity, and improve the drug solubility (Somiya
et al., 2017). In order to load EMVs, different methods have been invented and validated.
These methods include: incubation at room temperature (RT) with or without saponin
permeabilization, freeze-thaw cycles, and sonication. Loading of EMVs has been exploited
in several investigations, anticancer such as Paclitaxel (Saari et al., 2015), antioxidant such
as catalase enzyme to treat Parkinson disease (Haney et al., 2015) was successfully loaded,
and loaded EMVs showed a strong effect compared with free drug in in vivo and in vitro
model (Ha et al., 2016). In this work, we chose incubation at room temperature to load
growth factors into EMVs because the other methods mentioned above may affect the
nature and activity of the growth factor proteins.

Hypothesis
“The usage of EMVs as a novel and promising therapeutic tool in the wound
healing area will induce and enhance tissue repair process.”

Specific Aims
1. Evaluate the effect of EMVs on the wound healing process (cell migration and
proliferation).
2. Load the EMVs with growth factors (TGF-β, PDGF, FGF, and VEGF).
3. Assess the outcome of the loaded EMVs on wound healing process (cell migration and
proliferation) with compare to unloaded EMVs.
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Materials and methods
Reagents
Optimized Dulbecco's Modified Eagle Medium (DMEM) was purchased from
AddexBio.

Corning™ Regular Fetal Bovine Serum (FBS). HyClone™ Penicillin-

Streptomycin, HyClone™ Dulbecco's Phosphate Buffered Saline (DPBS), Gibco™
Trypsin-EDTA (0.25%), and Thermo Scientific™ Biolite 6 Well were purchased from
Fisher Scientific.

Cell Culture
The spontaneously immortalized skin keratinocyte cell line (HaCaT) from
AddexBio was cultured in optimized DMEM (contains 2 mM L-glutamine, 2 mM sodium
pyruvate, 4500 mg/L glucose, and 1500 mg/L sodium bicarbonate) supplemented with 10
% FBS, 1 % penicillin-streptomycin and incubated at 37 oC with 5 % CO2 in a humidified
atmosphere.

EMVs release and isolation
HaCaT and Macrophage cells were cultured respectively in serum free DMEM and
Ham's F-12 media for 48 h to enhance the release of keratinocytes derived microvesicles
(KMVs.) and macrophages derived microvesicles (MMVs) (Silva et al., 2015). After 48 h,
the medium was collected and centrifuged at 500 x g for 10 mins followed by 2000 x g for
20 minutes to remove cell debris using Eppendorf

®

centrifuge 5810 R. Then the

supernatant was Centrifuged at 24,000 x g for 2 hours using a S0RVALL® Discovery M120
SE ultracentrifuge to isolate the KMVs and MMVs. Isolated KMVs and MMVs were
reconstituted in DMEM/0.5 % FBS and stored at -80 oC.
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EMVs Loading
The EMVs were incubated for 1.5 hours at room temperature with PDGF, VEGF,
FGF, and TGF–beta (25 ng/ml of each). They were then ultra-centrifuged for 3 hours at
176 K G to re-pellet the EMVs., followed by 2-time wash with PBS to remove any extra
vesicles growth factors remained (Saari et al., 2015).

Nanoparticle tracking analysis (NTA)
NanoSight (NS300) with a 405-nm laser instrument was used to detect the presence
of EMVs particles (Figure 1). 10 microliters of EMVs sample was diluted 70 times in 690
µl Filtered PBS and three 30 second videos were recorded using camera level 13 at 25
frames per second. The data were analyzed using NTA software 3.0 software (Malvern
Instruments) which was optimized to first identify and then track each particle on a frameby-frame basis. The detection threshold optimized for each sample and screen gain at 5 to
track as many particles as possible with minimal background (JinjuWang et al., 2016, Saari
et al., 2015).

Figure 1: Average Concentration / Size of Extracellular microvesicles.
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Wound-scratch assay model
In this model, Epidermal keratinocytes were seeded into 6 well plates (150,000
cell/well). After wells Confluency, cells were starved in DMEM media supplemented with
low FBS concentration (0.5 %) overnight. On the next day, wound scratches were made
using a 10 µl pipette tip, and single dose of EMVs in DMEM/0.5 % FBS was added (2ml/
well). The wells were visualized by 10 x magnification power of EVOS XL Core Cell
Imaging System with CMOS camera sensor at zero time and after 72 hours. The images
were analyzed using Mat lab software to measure the wound area in pixels. To convert area
in pixels to microns, we used the following equation (Stpierre, & Shetty 2008):
(µm2/pixel) = Physical length of a pixel on camera sensor (12) / total magnification power
(10) = (1.2 µm2 = 1 pixel).

Cell Proliferation Assay (MTT Assay)
Colorimetric

3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl

tetrazolium

bromide

(MTT) assay kit (5 mg/ml in RPMI-1640 without phenol red) from Sigma was used to
assess the metabolic (reduction) activity of NAD(P)H-dependent cellular oxidoreductase
enzymes on converting yellow MTT dye to purple formazan, which reflect the number of
viable cells. MTT stock solution (5 mg/cc) is appended to each culture being assayed to
equal one-tenth the original culture volume and incubated for 4 hours. At the final stage of
the incubation period the medium was removed and the converted dye was solubilized with
acidic isopropanol (0.1 N HCl in absolute isopropanol). Absorbance of converted dye was
measured at a wavelength of 570 nm using micro plate reader (Gumustas, et al., 2016).
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Growth Factors Analysis
In order to analyze the growth factors levels inside the microvesicles, we used the
Bio-PLex system. 100μl 1XPBS was added to each sample, and protein concentration was
determined using the Bradford assay. A (Bio-Rad) BioPlex 96 well plate was set up with
50 µl of the sample and duplicated for cytokine analysis using Bio-Plex (Bio-Rad) Human
Cytokine 27-Plex Group 1 assay kits. To each well. Buffer and magnetic beads were added
and washed on the magnetic plate washer. The plate was run on the Bio-Plex 200 system
at a low PMT setting followed by high PMT according to Bio-Rad instructions.

PDGF-bb
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Figure 2. shows the level of FGF-b inside the loaded and
un-loaded EMVs from keratinocytes and macrophages.
“*” means that the level of FGF-b is more than standard
range.

*

*

#
Keratinocytes
loaded EMVs

Macrophages unloaded EMVs

Macrophages
loaded EMVs

Figure 3. shows the level of PDGF-bb inside the loaded and
un-loaded EMVs from keratinocytes and macrophages.
“*” means that the level of PDGF-bb is more than standard
range. “#” means that the level of PDGF-bb is less than the
standard range.
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VEGF
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Figure 4. shows the level of VEGF inside the loaded and un-loaded EMVs from
keratinocytes and macrophages. “#” means that the level of VEGF is less than
standard range.

Statistical analysis
The data analysis was conducted by using the Prism 6 software. The Experiment
was performed and repeated three times with independent HaCaT cultures. Wound area,
wound healing, and migration rate data are represented as mean ± SEM, analyzed using ttest with unequal variances and one-way ANOVA test. The results were considered
significant at P ≤ 0.05.

Results
Several studies have discussed the potential role of microvesicles in tissue repair
due to their role in intercellular communication (Saari et al., 2015). Therefore, in this study,
the wound - scratch assay was performed to examine whether treatment with EMVs
accelerate the wound closure of a wounded monolayer of differentiated and living skin
keratinocytes (HaCaT). The wounded areas in both groups were created by scratching the
plates with monolayer cells. The initial wounded area in both groups was similar with no
significant difference (P > 0.05) (Figure 5).
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Figure 5: Shows the Initial Wound Area in the Control, KMVs treated, LKMVs treated, MMVs treated,
and LMMVs Groups at zero time with no significant difference in wound area between the Groups (P >
0.05).

Table 1: Average of initial wound area at zero
Dependent variable: wound area
Groups
Mean
Std.
Deviation
Control
1.320
0.4421
MVs
1.142
0.4219
LKMVs
1.384
0.4861
MMVs
1.154
0.2767
LMMVs
1.372
0.3143
ANOVA: single factor: F= 1.908, df (4, 117), (P > 0.05).

S.E.M ±
0.07368
0.07703
0.1036
0.06187
0.08400

N
36
30
22
20
14

In the control group, the cells showed little ability to repair the wound area, whereas
in EMVs and LEMVs treated groups, the cells were shown to be able to repair the wound
area (Figure 6 A-J).
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Figure 6. Wound scratch assay shows EMVs and LEMVs from macrophages and keratinocytes accelerate
wound closure. Representative inverted microscope images depicting EMVs and LEMVs potential impact
on cell migration in differentiated, live HaCaT cells. In the control group (A, B), cells cultivated in 0.5 %
FBS/DMEM from the time of wounding: 0 h (A) and 72 h (B) after wounding. In EMVs and LEMVs treated
groups (C - J), cells cultivated in 0.5 % FBS/DMEM with single dose of EMVs or LEMVs from the time of
wounding: dose of EMVs and LEMVs from keratinocytes 0 h (C, E), and 72 h after wounding (D, F). dose
of EMVs and LEMVs from macrophages 0 h (G, I), and 72 h after wounding (H, J). (K- O) show the new
cells file the wound area of (B, D, F, H, J) after 72 h (n = 3).

Wound area was measured after 72 hours. There was a significant decrease in
wound area in LEMVs (LKMVs & LMMVs) and EMVs (KMVs & MMVs) treated groups
in comparison with the wounded area in the control group (P < 0.0001), whereas, LEMVs
was substantially declined as compared with EMVs (P < 0.01) (Figure 7).
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Figure 7: Shows Wounded Area Post 72 Hours in the Control, KMVs treated, LKMVs treated, MMVs
treated, and LMMVs treated groups. There is a significant decrease in wound area in the Treatment Groups
as compared with the Control Group (P < 0.0001), and substantial drop in wound area in LKMVs and
LMMVs as compared with control group (P < 0.0001), and KMVs and MMVs (P < 0.01).

Table 2: Average of wound area post 72 h
Dependent variable: wound area
Groups
Mean

Std.
Deviation
Control
1.045
0.4129
KMVs
0.5054
0.3232
LKMVs
0.3256
0.2958
MMVs
0.3938
0.3013
LMMVs
0.1369
0.09597
ANOVA: single factor: F= 29.55, DF (4, 117), (P <0.0001).

S.E.M ±

N

0.06882
0.05900
0.06307
0.06736
0.02565

36
30
22
20
14

In addition, the average percentage of wound healing was around three times higher
in the presence of EMVs. (57.85 % ±3.13, 69.84 % ± 4.87) when compared with the control
group (21.74 % ± 6.12) (P < 0.0001). Wound healing was four time higher in presence of
LEMVs (80.10 % ± 3.50, 90.87 % ± 2.00) as compared with the control, and around one
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time more (P < 0.01) as compared with EMVs group (57.85 % ±3.13, 69.84 % ± 4.87)
(Figure 8).
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Figure 8: Shows the Percent of Wound Healing in Control, KMVs treated, LKMVs
treated, MMVs treated, and LMMVs treated Groups with a significant increase in the
wound healing percentage in KMVs and MMVs Groups as compared with the Control
Group (P < 0.0001), and substantial increase wound healing percentage in LKMVs and
LMMVs groups as compared with control, KMVs, and MMVs (P < 0.0001).
Table 3: Average of wound healing percentage
Dependent variable: wound healing
Groups
Mean
Std. Deviation
S.E.M ±
Control
21.74
14.33
2.389
KMVs
57.85
16.86
3.130
LKMVs
80.10
16.45
3.506
MMVs
69.84
21.25
4.876
LMMVs
90.87
7.070
2.041
ANOVA: single factor: F= 70.22, DF (4, 117), (P <0.0001).

N
36
30
22
20
14

In addition, we noticed a clear change in cell morphology in EMVs and LEMVs
treated groups when compared with Control group. The cells residing at the edge of the
wounds became more stretched and elongated (Figure 6 K-O). Cell migration is defined
as cell movement into the wound area. For this reason, we calculated the cell migration
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rate for all groups, and it was significantly higher in EMVs and LEMVs treated group (P
< 0.0001) when compared with the control group, and it was higher in LMVs groups as
compared with EMVs groups (P < 0.0001) (Figure 9).
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Figure 9: Shows the Cells Migration Rate in the Control, KMVs, LKMVs, MMVs, and LMMVs Groups.
The cells migration rate in KMVs and MMVs Group were significantly higher as compared with the Control
Group (P < 0.0001), LKMVs and LMMVs groups were substantially remarkable as compared with KMVs,
MMVs, and Control (P < 0.0001),

Table 4: Average of migration rate (mm2/h)
Dependent variable: migration rate
Groups
Mean

Std.
S.E.M ±
Deviation
Control
0.003820
0.002256
0.0003760
KMVs
0.008810
0.003692
0.0006856
LKMVs
0.01470
0.004422
0.0009428
MMVs
0.01085
0.003472
0.0007964
LMMVs
0.01767
0.004030
0.001163
ANOVA: single factor: F= 53.86, DF (4, 117), (P <0.0001).
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N
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14

Furthermore, we calculated the area covered by the migrated cells in the both
groups based on their migration rate, this covered area was approximately threefold higher
in EMVs treated group, and four time in LEMVs treated groups (P < 0.0001) as compared
to the control group at 24, 48, and 72 hours (P < 0.0001). The migration rate in LEMVs
was one time more than EMVs groups (P < 0.01) (Figure 10).
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Figure 10: Shows the wound area covered by migrated cells was calculated at 24, 48, and 72 hours in the
Control, KMVs, LKMVs, MMVs, and LMMVs, this covered area was approximately threefold higher in
EMVs treated groups as compared with the control group at three time points (P < 0.0001). LEMVs groups
was almost four times more as compared with the control group (P < 0.0001), and one time more when
compared with the EMVs groups (P < 0.01).

Table 5: Average of wound covered area
Dependent variable: wound covered area
Group
Time (h)
Mean

Control

KMVs

LKMVs

MMVs

24
48
72
24
48
72
24
48
72
24
48
72

0.09169
0.1834
0.2751
0.2121
0.4242
0.6363
0.3529
0.7058
1.059
0.2534
0.5067
0.7601
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Std.
Deviation

S.E.M ±

0.05414
0.1083
0.1624
0.08714
0.1743
0.2614
0.1061
0.2123
0.3184
0.08692
0.1738
0.2608

0.009023
0.01805
0.02707
0.01591
0.03182
0.04773
0.02263
0.04526
0.06788
0.01944
0.03887
0.05831

N

36

30

22

20

0.4118
0.1029
24
0.8236
0.2058
LMMVs
48
1.235
0.3087
72
ANOVA: single factor: F= 72.75, DF (14, 351), (P <0.0001).
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0.05501
0.08251

14

MTT Assay
0.3
0.25

OD

0.2
0.15
0.1
0.05
0
Control

Keratinocytes Keratinocytes Macrophage Macrophage
unloaded
loaded MVs
unloaded
loaded MVs
MVs
MVs

Figure 11. shows the proliferation effect of EMVs

Discussion and Conclusion
In addition to the role in cell communication, EMVs have shown a regenerative
role in damaged tissues. For instant, K. R. Vrijsen et al. has reported the ability of EMVs
to improve endothelial cell migration and increase capillary formation in cardiac tissue
(Vrijsen et al., 2010). Camussi et al. has established that EMVs enhance the regeneration
process in liver tissue in rat models after 70 % hepatectomy (Camussi et al., 2009). In
kidneys, S. Bruno et al. has found that EMVs encourage tissue regeneration after acute
kidney injury in in vitro and in vivo models (Bruno et al., 2009).
21

Clinically, keratinocytes play an essential role in wound epithelization process, and
without them wounds cannot be healed. Moreover, in chronic non-healing wounds, it has
been found that compromised keratinocytes at wound edges are responsible for impaired
wound epithelization and closure (Stojadinovic et al. 2005).
The role of EMVs in conveying messages and transferring genes horizontally
between cells has been revealed by Ratajczak et al. and Waldenström et al., in addition to
their ability to induce the re-programing of recipient cells (Waldenström et al., 2012,
Ratajczak et al., 2006).
In this study, we demonstrated that EMVs and growth factors loaded EMVs derived
from keratinocytes and macrophages promoted cell migration, proliferation accelerated
wound closure in epidermal keratinocytes in vitro cell model. All these findings about the
role of EMVs in tissue repair, including our observation, support the hypothesis of potential
regenerative and therapeutic effects of EMVs and loaded EMVs in wound healing. Further
investigations are needed to study the potential therapeutic use of EMVs in wound healing.
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